Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The daily Top 10 COVID papers

  Bladder Cancer

  Free Subscription


1 Acta Biochim Biophys Sin (Shanghai)
1 Adv Respir Med
1 Aging (Albany NY)
1 Ann Oncol
1 BJU Int
1 BMC Immunol
1 BMC Urol
1 BMC Vet Res
1 Can Urol Assoc J
1 Cancer Cell Int
1 Cancer Lett
1 Cancer Radiother
1 Cancer Treat Res Commun
2 Cancers (Basel)
1 Cells
1 Curr Opin Urol
1 Diagnostics (Basel)
2 Eur Urol
1 Front Genet
1 Front Immunol
1 Front Oncol
1 Hereditas
1 Hum Cell
1 Immunotherapy
3 In Vivo
1 Int J Cancer
1 Int J Med Sci
1 Int J Mol Sci
1 Int J Radiat Oncol Biol Phys
1 Int Urol Nephrol
1 Iran J Pathol
2 J Cancer
1 J Clin Pathol
1 J Coll Physicians Surg Pak
1 J Pharm Pharmacol
1 Mol Cancer
1 Nat Commun
1 Onco Targets Ther
1 Pharmacol Res
1 Rapid Commun Mass Spectrom
1 Sci Transl Med
1 Toxicol Appl Pharmacol
1 Urol Oncol
1 Urologe A
1 Urologia

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Acta Biochim Biophys Sin (Shanghai)

  1. WANG X, Zhang R, Wu T, Shi Y, et al
    Successive treatment with naltrexone induces epithelial-mesenchymal transition and facilitates the malignant biological behaviors of bladder cancer cells.
    Acta Biochim Biophys Sin (Shanghai). 2021 Jan 7. pii: 6067264.
    PubMed         Abstract available

    Adv Respir Med

  2. STEPIEN A, Brudlo M, Stachura T, Marcinek P, et al
    Miliary pulmonary tuberculosis after the first dose of intravesical BCG instillation in a patient with high-grade bladder cancer.
    Adv Respir Med. 2020;88:628-629.

    Aging (Albany NY)

  3. YAN Y, Huang Z, Cai J, Tang P, et al
    Identification of a novel immune microenvironment signature predicting survival and therapeutic options for bladder cancer.
    Aging (Albany NY). 2020;12.
    PubMed         Abstract available

    Ann Oncol

  4. BANDINI M, Gibb EA, Gallina A, Raggi D, et al
    Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study().
    Ann Oncol. 2020;31:1755-1763.
    PubMed         Abstract available

    BJU Int

  5. RICHTERS A, Ripping TM, Kiemeney LA, Leliveld AM, et al
    Hospital volume is associated with postoperative mortality following radical cystectomy for treatment of bladder cancer.
    BJU Int. 2021 Jan 6. doi: 10.1111/bju.15334.
    PubMed         Abstract available

    BMC Immunol

  6. XIU W, Luo J
    CXCL9 secreted by tumor-associated dendritic cells up-regulates PD-L1 expression in bladder cancer cells by activating the CXCR3 signaling.
    BMC Immunol. 2021;22:3.
    PubMed         Abstract available

    BMC Urol

  7. CHEN D, Cheng L, Cao H, Liu W, et al
    Role of microRNA-381 in bladder cancer growth and metastasis with the involvement of BMI1 and the Rho/ROCK axis.
    BMC Urol. 2021;21:5.
    PubMed         Abstract available

    BMC Vet Res

  8. MUSSER ML, Viall AK, Phillips RL, Hostetter JM, et al
    Gene expression of prostaglandin EP4 receptor in three canine carcinomas.
    BMC Vet Res. 2020;16:213.
    PubMed         Abstract available

    Can Urol Assoc J

  9. GRAHAM CH, Pare JF, Cotechini T, Hopman W, et al
    Innate immune memory is associated with increased disease-free survival in bladder cancer patients treated with bacillus Calmette-Guerin.
    Can Urol Assoc J. 2021 Jan 4. pii: cuaj.7066. doi: 10.5489/cuaj.7066.
    PubMed         Abstract available

    Cancer Cell Int

  10. SHAO Y, Hu X, Yang Z, Lia T, et al
    Prognostic factors of non-muscle invasive bladder cancer: a study based on next-generation sequencing.
    Cancer Cell Int. 2021;21:23.
    PubMed         Abstract available

    Cancer Lett

  11. XIE R, Chen X, Chen Z, Huang M, et al
    Corrigendum to "Polypyrimidine tract binding protein 1 promotes lymphatic metastasis and proliferation of bladder cancer via alternative splicing of MEIS2 and PKM." [Canc. Lett. 449 (2019) 31-44].
    Cancer Lett. 2020 Dec 31. pii: S0304-3835(20)30687.

    Cancer Radiother

  12. CABAILLE M, Khalifa J, Tessier AM, Belhomme S, et al
    [A review of adaptive radiotherapy for bladder cancer].
    Cancer Radiother. 2021 Jan 2. pii: S1278-3218(20)30331.
    PubMed         Abstract available

    Cancer Treat Res Commun

  13. RHEA LP, Mendez-Marti S, Kim D, Aragon-Ching JB, et al
    Role of immunotherapy in bladder cancer.
    Cancer Treat Res Commun. 2020;26:100296.
    PubMed         Abstract available

    Cancers (Basel)

  14. LOPEZ-BELTRAN A, Cimadamore A, Blanca A, Massari F, et al
    Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer.
    Cancers (Basel). 2021;13.
    PubMed         Abstract available

  15. SILINA L, Maksut F, Bernard-Pierrot I, Radvanyi F, et al
    Review of Experimental Studies to Improve Radiotherapy Response in Bladder Cancer: Comments and Perspectives.
    Cancers (Basel). 2020;13.
    PubMed         Abstract available


  16. KOTOLLOSHI R, Holzer M, Gajda M, Grimm MO, et al
    SLC35F2, a Transporter Sporadically Mutated in the Untranslated Region, Promotes Growth, Migration, and Invasion of Bladder Cancer Cells.
    Cells. 2021;10.
    PubMed         Abstract available

    Curr Opin Urol

  17. HUGAR LA, Gilbert SM, Sexton WJ, Kamat AM, et al
    Immunotherapy in Bacillus Calmette-Guerin (BCG) unresponsive nonmuscle invasive bladder cancer.
    Curr Opin Urol. 2020;Publish Ahead of Print.
    PubMed         Abstract available

    Diagnostics (Basel)

  18. SZARVAS T, Hoffmann MJ, Olah C, Szekely E, et al
    MMP-7 Serum and Tissue Levels Are Associated with Poor Survival in Platinum-Treated Bladder Cancer Patients.
    Diagnostics (Basel). 2020;11.
    PubMed         Abstract available

    Eur Urol

  19. PERERA-BEL J, Bellmunt J
    Reply to Anirban P. Mitra, Tanner Miest, and Colin P.N. Dinney's Words of Wisdom re: Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.euru
    Eur Urol. 2021 Jan 5. pii: S0302-2838(20)31024.

  20. SYLVESTER RJ, Rodriguez O, Hernandez V, Turturica D, et al
    European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel.
    Eur Urol. 2021 Jan 5. pii: S0302-2838(20)31019.
    PubMed         Abstract available

    Front Genet

  21. JIANG A, Liu N, Bai S, Wang J, et al
    The Construction and Analysis of Tumor-Infiltrating Immune Cells and ceRNA Networks in Bladder Cancer.
    Front Genet. 2020;11:605767.
    PubMed         Abstract available

    Front Immunol

  22. WU X, Lv D, Cai C, Zhao Z, et al
    A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer.
    Front Immunol. 2020;11:590618.
    PubMed         Abstract available

    Front Oncol

  23. ZHENG Z, Mao S, Zhang W, Liu J, et al
    Dysregulation of the Immune Microenvironment Contributes to Malignant Progression and Has Prognostic Value in Bladder Cancer.
    Front Oncol. 2020;10:542492.
    PubMed         Abstract available


  24. CHEN Z, Liu G, Liu G, Bolkov MA, et al
    Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypes.
    Hereditas. 2021;158:1.
    PubMed         Abstract available

    Hum Cell

  25. TANG C, Wu Y, Wang X, Chen K, et al
    LncRNA MAFG-AS1 regulates miR-125b-5p/SphK1 axis to promote the proliferation, migration, and invasion of bladder cancer cells.
    Hum Cell. 2021 Jan 5. pii: 10.1007/s13577-020-00470.
    PubMed         Abstract available


  26. SAMAHA H, Samaha R, Sarkis J, Kattan J, et al
    Maintenance avelumab in metastatic bladder cancer as a step towards sequencing immunotherapy.
    Immunotherapy. 2021 Jan 5. doi: 10.2217/imt-2020-0261.

    In Vivo

  27. LIEVORE E, Runza L, Ghidini M, Galassi B, et al
    Micropapillary Bladder Cancer Metastatic to the Breast: A Case Report and Brief Literature Review.
    In Vivo. 2021;35:453-459.
    PubMed         Abstract available

  28. FERINI G, Cacciola A, Parisi S, Lillo S, et al
    Curative Radiotherapy in Elderly Patients With Muscle Invasive Bladder Cancer: The Prognostic Role of Sarcopenia.
    In Vivo. 2021;35:571-578.
    PubMed         Abstract available

  29. GOUTAS D, Tzortzis A, Gakiopoulou H, Vlachodimitropoulos D, et al
    Contemporary Molecular Classification of Urinary Bladder Cancer.
    In Vivo. 2021;35:75-80.
    PubMed         Abstract available

    Int J Cancer

  30. XU T, Li HT, Wei J, Li M, et al
    Epigenetic plasticity potentiates a rapid cyclical shift to and from an aggressive cancer phenotype.
    Int J Cancer. 2020;146:3065-3076.
    PubMed         Abstract available

    Int J Med Sci

  31. ZHENG X, Qiu S, Yang L, Wei Q, et al
    Comparison of survival outcomes between primary and secondary muscle-invasive bladder cancer: An updated meta-analysis.
    Int J Med Sci. 2021;18:505-510.
    PubMed         Abstract available

    Int J Mol Sci

  32. WYSOCKA M, Romanowska A, Gruba N, Michalska M, et al
    A Peptidomimetic Fluorescent Probe to Detect the Trypsin beta2 Subunit of the Human 20S Proteasome.
    Int J Mol Sci. 2020;21.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  33. MARCQ G, Souhami L, Cury FL, Salimi A, et al
    Phase I Trial of Atezolizumab plus Trimodal Therapy in Patients with localized Muscle-Invasive Bladder Cancer.
    Int J Radiat Oncol Biol Phys. 2021 Jan 6. pii: S0360-3016(20)34729.
    PubMed         Abstract available

    Int Urol Nephrol

  34. FARAJ KS, Navaratnam AK, Eversman S, Elias L, et al
    Use of treatment pathway improves neoadjuvant chemotherapy use in muscle-invasive bladder cancer.
    Int Urol Nephrol. 2021 Jan 3. pii: 10.1007/s11255-020-02752.
    PubMed         Abstract available

    Iran J Pathol

  35. KHAYAMZADEH M, Aliakbari F, Zolghadr Z, Emadeddin M, et al
    Five-Year Survival Rate of Bladder Cancer in Iran during 2001-2007.
    Iran J Pathol. 2021;16:69-74.
    PubMed         Abstract available

    J Cancer

  36. LI F, Xie W, Fang Y, Xie K, et al
    HnRNP-F promotes the proliferation of bladder cancer cells mediated by PI3K/AKT/FOXO1.
    J Cancer. 2021;12:281-291.
    PubMed         Abstract available

  37. BI H, Yan Y, Wang D, Qin Z, et al
    Predictive value of preoperative lymphocyte-to-monocyte ratio on survival outcomes in bladder cancer patients after radical cystectomy.
    J Cancer. 2021;12:305-315.
    PubMed         Abstract available

    J Clin Pathol

  38. OLKHOV-MITSEL E, Hodgson A, Liu SK, Vesprini D, et al
    Immune gene expression profiles in high-grade urothelial carcinoma of the bladder: a NanoString study.
    J Clin Pathol. 2021;74:53-57.
    PubMed         Abstract available

    J Coll Physicians Surg Pak

  39. MATI Q, Qamar S, Ashraf S, Khokhar MA, et al
    Tissue Nuclear Matrix Protein Expression 22 in Various Grades and Stages of Bladder Cancer.
    J Coll Physicians Surg Pak. 2020;30:1321-1325.
    PubMed         Abstract available

    J Pharm Pharmacol

  40. XIANG Y, Zhang Q, Wei S, Huang C, et al
    Paeoniflorin: a monoterpene glycoside from plants of Paeoniaceae family with diverse anticancer activities.
    J Pharm Pharmacol. 2020;72:483-495.
    PubMed         Abstract available


  41. LENIS AT, Lec PM, Chamie K
    Urinary Diversion.
    JAMA. 2020;324:2222.

    Mol Cancer

  42. YANG X, Ye T, Liu H, Lv P, et al
    Expression profiles, biological functions and clinical significance of circRNAs in bladder cancer.
    Mol Cancer. 2021;20:4.
    PubMed         Abstract available

    Nat Commun

  43. VANDEKERKHOVE G, Lavoie JM, Annala M, Murtha AJ, et al
    Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer.
    Nat Commun. 2021;12:184.
    PubMed         Abstract available

    Onco Targets Ther

  44. ZHAO M, Zhang M, Wang Y, Yang X, et al
    Prognostic Value of Preoperative Albumin-to-Alkaline Phosphatase Ratio in Patients with Muscle-Invasive Bladder Cancer After Radical Cystectomy.
    Onco Targets Ther. 2020;13:13265-13274.
    PubMed         Abstract available

    Pharmacol Res

    The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
    Pharmacol Res. 2020;151:104567.
    PubMed         Abstract available

    Rapid Commun Mass Spectrom

  46. CHEN YT, Ou Yang WT, Juang HH, Chen CL, et al
    Proteomic characterization of arsenic and cadmium exposure in bladder cells.
    Rapid Commun Mass Spectrom. 2020;34 Suppl 1:e8578.
    PubMed         Abstract available

    Sci Transl Med

  47. ORESTA B, Pozzi C, Braga D, Hurle R, et al
    Mitochondrial metabolic reprogramming controls the induction of immunogenic cell death and efficacy of chemotherapy in bladder cancer.
    Sci Transl Med. 2021;13.
    PubMed         Abstract available

    Toxicol Appl Pharmacol

  48. YEH BW, Yu LE, Li CC, Yang JC, et al
    The protoapigenone analog WYC0209 targets CD133+ cells: A potential adjuvant agent against cancer stem cells in urothelial cancer therapy.
    Toxicol Appl Pharmacol. 2020;402:115129.
    PubMed         Abstract available

    Urol Oncol

  49. SMELSER WW, Randall JH, Caldwell J, Glavin K, et al
    Characterization of perioperative androgen profiles in men with bladder cancer undergoing radical cystectomy.
    Urol Oncol. 2021 Jan 1. pii: S1078-1439(20)30642.
    PubMed         Abstract available

    Urologe A

  50. TAMALUNAS A, Schulz GB, Rodler S, Apfelbeck M, et al
    [Systemic treatment of bladder cancer].
    Urologe A. 2021 Jan 4. pii: 10.1007/s00120-020-01420.
    PubMed         Abstract available


  51. GANDI C, Vaccarella L, Bientinesi R, Racioppi M, et al
    Bladder cancer in the time of machine learning: Intelligent tools for diagnosis and management.
    Urologia. 2021 Jan 5:391560320987169. doi: 10.1177/0391560320987169.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.